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Abstract 
Background 
Policies for allocating deceased donor kidneys have recently shifted from allocation based on 
Human Leucocyte Antigen (HLA) tissue matching in the UK and USA. Newer allocation 
algorithms incorporate waiting time as a primary factor, and in the UK, young adults are also 
favoured. However, there is little contemporary UK research on the views of stakeholders in 
the transplant process to inform future allocation policy. This research project aimed to 
address this issue. 
Methods 
Discrete Choice Experiment (DCE) questionnaires were used to establish priorities for kidney 
transplantation among different stakeholder groups in the UK. Questionnaires were targeted 
at patients, carers, donors / relatives of deceased donors, and healthcare professionals. 
Attributes considered included: waiting time; donor-recipient HLA match; whether a 
recipient had dependents; diseases affecting life expectancy; and diseases affecting quality of 
life. 
Results 
Responses were obtained from 908 patients (including 98 ethnic minorities); 41 carers; 48 
donors / relatives of deceased donors; and 113 healthcare professionals. The patient group 
demonstrated statistically different preferences for every attribute (i.e. significantly different 
from zero) so implying that changes in given attributes affected preferences, except when 
prioritizing those with no rather than moderate diseases affecting quality of life. The 
attributes valued highly related to waiting time, tissue match, prioritizing those with 
dependents, and prioritizing those with moderate rather than severe diseases affecting life 
expectancy. Some preferences differed between healthcare professionals and patients, and 
ethnic minority and non-ethnic minority patients. Only non-ethnic minority patients and 
healthcare professionals clearly prioritized those with better tissue matches. 
Conclusions 
Our econometric results are broadly supportive of the 2006 shift in UK transplant policy 
which emphasized prioritizing the young and long waiters. However, our findings suggest the 
need for a further review in the light of observed differences in preferences amongst ethnic 
minorities, and also because those with dependents may be a further priority. 
Trial registration 
This was not a clinical trial and so it did not require clinical trial registration. Ethical approval 
was obtained from Warwickshire Local Research Ethics Committee (reference number 05 / 
Q2803 / 86). 
Keywords 
Renal transplant, Allocation, Choice experiment, Stakeholder. 
Background 
In the United Kingdom (UK) in January 2011 there were 6,610 patients awaiting renal 
transplantation (a figure which had risen by 8% annually since 2004). In the previous year 
(2009–10), only 1,482 patients received deceased donor transplants, and 1,038 received live 
donor transplants [1]. A growing imbalance between demand and supply led to the Organ 
Donation Taskforce Report in 2008 [2] outlining strategies to increase UK organ supply by 
50% within 5 years. However, despite the resultant increase in organ supply, demand still 
continues to outstrip supply. So criteria remain necessary to allocate the limited supply of 
kidneys which are available for transplantation. 
A transplant policy based on efficiency criteria would require that organs be transplanted to 
patients deriving greatest health benefit. Criteria to address equity of access may conflict with 
efficiency ones. Patients waiting a long time may be selected for transplant on equity grounds 
even if someone else, who has not waited as long, would obtain greater health benefits from 
transplantation. In 2006, UK transplant policy was re-appraised. The previous policy was 
thought to disadvantage those with less common tissue types and blood groups, especially 
ethnic minorities. This population is also at higher risk of kidney disease [3]. African 
Caribbeans and Asians have a 3–4 times greater risk of end stage renal disease [2] related to a 
higher prevalence of type 2 diabetes [4]. Increased risk of renal disease in these groups is also 
associated with increased risk of co-morbidities such as hypertension [5] and cardiovascular 
disease [6]. Moreover, ethnic minorities donate fewer organs [6], so individual patients are 
less likely to obtain closely matched transplants. 
The 2006 re-appraisal led to reduced priority being attached to HLA matching in the UK, and 
allowed consideration of other criteria [7]. The resulting guidelines [8] suggested more 
priority should be given to long waiters and paediatric and younger adult recipients. Research 
from the USA and Australia had, indicated such changes would be acceptable to 
professionals and patients [9,10]. Although there was some excellent UK research to inform 
prioritization [11], this research did not adopt DCE methodology, unlike ours. 
In this analysis we have used Discrete Choice Experiments (DCEs) in order to establish 
respondent‟s valuation of different kidney transplant allocation criteria, and how they might 
trade-off gains in relation to one transplant allocation criterion, for losses in relation to 
another transplant allocation criterion. DCEs involve the application of a stated preference 
technique in order to establish a respondent‟s valuation of attributes or characteristics of a 
good or service or health state. DCEs are increasingly being used to address priority setting 
issues in healthcare, both in primary care [12], and secondary care [13,14]. Some DCE 
research has been published on general transplantation issues, including assessing factors 
influencing willingness to donate body parts [15] and a DCE to establish UK priorities for 
liver transplantation [16,17]. In renal transplantation, the first DCE findings internationally 
emanated from our study conducted in the UK [18]. This publication focused solely on 
assessing whether patient preferences varied by ethnicity and gender. More recently, DCE 
research has been undertaken in Canada relating to patient and healthcare professional 
preferences for chronic kidney disease (CKD) care more generally (although not specifically 
focused on kidney transplantation) [19]. 
The current paper provides more extensive evidence on the preferences of various 
stakeholder groups alongside those of patients than our earlier paper [18]. These groups 
include patients, renal healthcare professionals, renal carers, and live donors / relatives of 
deceased donors. Unlike the general public (who may lack personal experience of renal 
disease) all these „expert‟ stakeholder groups will have a direct interest in priorities for 
kidney transplant allocation, either because they have renal disease themselves (patients) or 
care for those with such a disease (renal carers / renal healthcare professionals). Moreover, 
live donors or relatives of deceased donors are concerned to ensure kidneys are appropriately 
allocated. Therefore research to improve understanding of the preferences of these different 
stakeholder groups should help inform the policy debate about transplantation. 
Methods 
Overview 
This Discrete Choice Experiment (DCE) study assumed that respondents‟ valuations of 
different kidney transplant allocation criteria can be decomposed into component parts 
known as attributes. The DCE involved respondents making repeated hypothetical pairwise 
choices in which they expressed their stated preferences about which of two transplant 
recipients (differing in these pre-defined characteristics or attributes) should receive a kidney. 
DCE respondents‟ trade-offs were established so that weightings given to different recipient 
characteristics (attributes) could be quantified. The pilot study for this research began in 
2005; the main study started in 2006 with final data analysis completed during 2007–09. 
Pilot exercise 
Although some DCEs have been undertaken without undertaking a pilot exercise first, the 
benefits of initial piloting and analysis of pilot data econometrically are considerable. We 
therefore undertook a rigorous pilot exercise using both qualitative and quantitative methods. 
For full details see Additional file 1. Attributes tested in the pilot included waiting time, 
tissue match, employment status, number of dependents, recipient age and various diseases 
affecting recipient health. Attributes and level selection was mainly informed by discussions 
with clinicians. Given the number of attributes and levels selected, we needed to design a 
DCE questionnaire which used a limited number of different choice scenarios, which would 
be sufficient to infer choice information. However, we also invited pilot respondents to 
suggest other possible attributes and rank them in order of priority (alongside those already in 
the questionnaire). Attributes tested in the pilot included waiting time, tissue match, 
employment status, number of dependents, recipient age, patient compliance, whether illness 
could be regarded as „self-inflicted‟ and various diseases (co-morbidities) affecting recipient 
health. Early during the pilot some respondents expressed disquiet about the employment 
attribute, arguing it represented unwarranted discrimination against the retired or those 
unemployed because of illness. We therefore asked all respondents whether this should be 
included. Most respondents said „no‟, so this was omitted. We used the computer package 
SPEED (software designed to establish choice sets for DCEs [20]) for the pilot DCE to 
generate such an orthogonal main effects design. We paired choices generated by SPEED to 
minimize attribute overlap and level imbalance [21]. The pilot exercise analysed 60 responses 
to establish appropriate attributes and levels for use in the final DCE questionnaire. 
Identifying attributes and levels for final DCE 
The pilot exercise analyzed 60 responses to ascertain attributes and levels for the final DCE 
using Random Effects Probit. All the attributes (with the exception of the employment status 
attribute) proved significant at the 5% level (i.e. implying that the attribute would affect a 
respondent‟s choice of who to prioritize for kidney transplant). Final pilot findings from 
attribute rankings indicated that the employment status attribute was far from highly ranked 
and it was therefore removed. The following inclusions were warranted, with some limited 
changes. Respondents thought people with dependents ought to be prioritized, but most 
considered adult as well as child dependents should be included, so this attribute was 
amended to include adults. Age was considered relevant, but the recipient age ceiling was 
reduced to 65 because clinicians indicated that transplantation was less likely amongst over 
65s. Although highly ranked separately, when combined the life expectancy and other 
recipient diseases (non-CKD co-morbidities) attributes resulted in unrealistic DCE scenarios. 
For example, one pairwise choice resulted in respondents choosing between a 70 year old 
with severe arthritis with 12 years life expectancy, and a 45 year old without co-morbidities 
with a shorter life expectancy. Such a comparison did not make sense since a 45 year old 
without co-morbidities would be expected to have a longer life expectancy. So, the life 
expectancy attribute was replaced with one indicating whether a potential recipient had 
diseases predominantly affecting life expectancy. This provided more realistic scenarios and 
improved DCE design. 
Other attributes highly ranked in the pilot exercise included „patient compliance‟ and whether 
illness was „self-inflicted‟. However, advice from medical professionals highlighted the fact 
that unlike „liver transplantation‟ renal transplantation was rarely required because of alcohol 
or drug misuse, so this was not a particularly relevant consideration to underpin attributes and 
levels for the DCE. Also patients who are thought likely to abuse their bodies or be non-
compliant would not be transplanted. On this basis, it was decided to exclude this attribute. 
Table 1 lists the final attributes and levels selected for use in the DCE questionnaires. Copies 
of the questionnaires are provided in Additional file 2. 
Table 1 Details of final attributes and levels used for Discrete Choice Experiment (DCE) 
questions 
Attribute Variable name Levels Interpretation of 
coefficients 
Time spent awaiting 
transplantation 
Wait 1 month, 2 years, and 10 years. Indirect utility of each 1 year 
reduction in transplant 
recipient waiting time. 
Tissue type matching. Tiss Non-favourable match: 86% average 
kidney survival rate post-transplant. 
Indirect utility of prioritizing 
people for each 1% 
improvement in kidney 
survival. 
Favourable match: 89% average kidney 
survival rate post-transplant. 
Perfect match: 90% average kidney 
survival rate post-transplant. 
How many child or adult 
dependents recipients 
have 
Dep None, 1, or 4 dependents. Indirect utility of each 
additional dependent. 
Recipient age Age 20 years, 45 years, and 65 years Indirect utility for each 1 year 
reduction in recipient age. 
Diseases predominantly 
affecting life expectancy 
dis1 No disease affecting life expectancy (other 
than Kidney disease) vs. moderate disease 
(uncontrolled hypertension or obesity) & 
Kidney disease. 
Indirect utility of having no 
rather than moderate disease 
predominantly affecting life 
expectancy. 
dis2 Moderate disease (uncontrolled 
hypertension or obesity) affecting life 
expectancy vs. severe disease (heart attack, 
stroke, or diabetes with complications). 
Indirect utility of having 
moderate disease rather than 
severe disease predominantly 
affecting life expectancy. 
Diseases predominantly 
affecting quality of life 
ill1 No disease affecting quality of life (other 
than Kidney disease) vs. moderate disease 
(mild asthma). 
Indirect utility of having no 
disease rather than a moderate 
disease predominantly 
affecting quality of life. 
ill2 Moderate disease (mild asthma) affecting 
quality of life vs. severe disease (severe 
arthritis). 
Indirect utility of having a 
moderate disease rather than a 
severe disease predominantly 
affecting quality of life. 
The pilot questionnaire contained an explanatory preamble which described the attributes and 
levels included. Transplant survival rates were presented from UK Transplant and it was 
explained that these were contingent upon donor / recipient tissue match. Although transplant 
survival rates were available for longer time horizons, we wanted to avoid information 
overload and therefore only presented 12 month survival rates. The pilot confirmed that 
explanatory information was easy to understand. 
Final Discrete Choice Experiment (DCE) 
We used a binary dependent variable model in order to force a choice. This is because, in 
reality, transplant decisions have to be made and medical professionals face a forced choice 
when allocating kidneys because of donor scarcity. Moreover, pilot interviews revealed that 
many respondents felt uncomfortable with deciding who to transplant. Therefore, it was 
judged that including a „cannot decide‟ option might have triggered such a response from 
people who in reality were not indifferent. An alternative would have been to allow choices 
between more than 2 potential recipients using a multinomial model, or to have more 
attributes and levels; but this would have complicated decision making [22]. Moreover, since 
many renal patients suffer from fatigue we wanted to avoid complicated decisions, because 
when complexity increases there is evidence that respondents may be more inclined to use 
simplifying heuristics [23] compromising response reliability. Copies of the final DCE 
questionnaires are provided in Additional file 2. 
The final DCE design was again an Orthogonal Main Effects Plan (OMEP) design involving 
independent valuation of attributes. To ensure a perfectly orthogonal design and improve 
efficiency we used an OMEP design supplied by leading DCE designers [24] rather than 
SPEED as used in the pilot exercise. We also blocked 18 choices into 2 blocks of 9 questions 
(versions A and B) to reduce respondent fatigue and limit the patient questionnaire to 10 
pages. Respondents were asked to choose between transplanting patient A with particular 
attribute levels or patient B with different levels (see Additional file 2 for examples). 
Questionnaire distribution 
We included an information leaflet and freepost envelope in the National Kidney 
Federation‟s newsletter „Kidney Life‟ (circulation c.20,000). The leaflet invited patients, 
carers, donors or healthcare professionals to request a DCE questionnaire. Individuals who 
replied were sent a questionnaire, along with a covering letter, consent form, and freepost 
reply envelope for the completed questionnaire. Individuals who did not return a 
questionnaire were not contacted again. Questionnaires were also posted directly to members 
of the British Organ Donor Society, healthcare professionals listed in the UK Transplant 
service directory, and to non-transplanting units with transplant coordinators or transplant 
physicians. Relatives of deceased donors were targeted via the British Organ Donation 
Society (BODY). To increase ethnic minority responses we provided questionnaires in a 
person‟s preferred language. A reputable translation organization was used to translate 
questionnaires in Punjabi, Hindi, Bengali, Gujarati and Urdu. A bilingual researcher 
administered the questionnaires upon non-English speaking patients and checked the 
questionnaire‟s translation accuracy. We obtained additional responses from Ealing NHS 
Trust, and from University Hospital, Coventry using translated questionnaires to increase 
levels of ethnic minority participation. 
Assessing the representativeness of respondent sample 
In order to assess representativeness, we used UK Renal Registry data (when available); 
figures were extracted for transplant success rates. Other relevant patient data were not 
available i.e. patients with failed transplant, awaiting a transplant, on dialysis, or with kidney 
disease not requiring dialysis. UK Renal Registry data also does not record detailed ethnicity 
information for some sub-groups of respondents, so detailed patient data is not available for 
all sub-groups. 
Econometric / statistical analysis models 
Two models were used for analysis (for full details refer to Additional file 3). Random 
Effects probit (model 1 and 2) was used to establish different stakeholder preferences.  Model 
1 used a series of dummy variables to ascertain whether preferences for specific attributes 
differed amongst carers, donors / relatives of deceased donors, and healthcare professionals 
compared with the patient respondents group. 
Model 2 compared the preferences of ethnic minority and white majority patients. Again a 
series of dummy variables were used to establish whether preferences differed between ethnic 
minority and other patients for specific attributes. 
Marginal Rate of Substitution (MRS) 
Data were analysed in terms of a measure of marginal rate of substitution (MRS) which 
related differences in other attributes (potential transplant priority criteria) to waiting time for 
renal transplants. Analysis examined whether differences in MRS were statistically 
significant between stakeholder groups for specific attributes (using Wald tests). We also 
used the Delta method [25] with command „nlcom‟ in STATA to estimate 95% confidence 
intervals. Full details of the approach used to derive MRS are provided in Additional file 4 
(Table A1). Wald tests using „testnl‟ in STATA were used to establish whether MRS differed 
significantly between groups; comparing patients with carers, donors and healthcare 
professionals (model 1); and ethnic minority patients vs. white majority patients (model 2). 
For example, to establish whether preferences for tissue matching differed between ethnic 
and non-ethnic minorities (model 2), the null hypothesis was that tissue match MRS was 
identical for both (p ≤ 0.05 indicated a difference at the 5% level). 
Results 
Sample characteristics 
Table 2 presents respondent characteristics. We obtained 908 patient responses; 18 additional 
responses from Ealing NHS Trust and 5 from University Hospital, Coventry were obtained 
using translated questionnaires. UK Renal Registry data [26,27] was used to assess patient 
sample representativeness. 508 /908 patient respondents (55.9%) were male, 397 / 908 
(43.7%) were female, and 3 / 908 (0.3%) not reported. Renal Registry data [26] similarly 
indicates a slightly higher proportion of male than female patients across age groups. The 
average patient age in the sample was 54.9 years (median 57 years), coinciding with the 
Renal Registry data median age (57.3 years) [27]. Of the 895/ 908 patients indicating 
ethnicity, 799 / 895 (89.3%) were white British and 27 / 895 (3%) were other white 
background (e.g. Irish), giving a total of 92.3% white patients. UK data [26] indicates that 
79.7% of renal patients are white. So white respondents are over-represented in our survey. 
Overall, 69 / 895 (7.7%) patients indicating ethnicity were non-white, compared with an 
expected 20.3% incidence rate [26], and 50 / 69 of the non-white patients were South Asians 
(5.6% of those indicating ethnicity) compared to an anticipated 10.5% [26]. 
Table 2 Details of characteristics of questionnaire respondent samples 
 Patients (n = 908) Carers (n=41) Donors (n =48) Healthcare workers (n=113) 
AGE     
Mean age 54.88 years 52.37 years 54.67 years 43.23 years 
GENDER     
Male 508 (55.9%) 10 (24.4%) 14 (29.2%) 51 (45.1%) 
Female 397 (43.7%) 31 (75.6%) 34 (70.8%) 61 (54.0%) 
Not indicated 3 (0.3%) 0 (0%) 0 (0%) 1 (0.9%) 
ETHNICITY     
White (British) 799 (88%) 38 (92.7%) 44 (91.7%) 89 (78.8%) 
White ethnic minorities 27 (2.9%) 1 (2.4%) 1 (2.1%) 9 (8%) 
Non-white ethnicity (excluding Asians) 19 (2.1%) 1 (2.4%) 0 (0%) 2 (1.8%) 
Non-white ethnicity (Asians) 50 (5.5%) 1 (2.4%) 1 (2.1%) 9 (8%) 
Not indicated 13 (1.4%) 0 (0%) 2 (4.2%) 4 (3.5%) 
DEPENDENT CHILDREN     
0 755 (83.1%) 33 (80.5%) 36 (75%) 51 (45.1%) 
1 72 (7.9%) 2 (4.9%) 5 (10.4%) 22 (19.5%) 
2 49 (5.4%) 5 (12.2%) 2 (4.2%) 26 (23.0%) 
3 12 (1.3%) 0 (0%) 3 (6.3%) 9 (8.0%) 
> 3 7 (0.8%) 1 (2.4%) 1 (2.1%) 3 (2.7%) 
Not indicated 13 (1.4%) 0 (0%) 1(2.1%) 2 (1.8%) 
DEPENDENT ADULTS     
0 750 (82.6%) 16 (39.0%) 39 (81.2%) 98 (86.7%) 
1 121 (13.3%) 17 (41.5% 6 (12.5%) 11 (9.7%) 
2 17 (1.9%) 6 (14.6%) 2 (4.2%) 3 (2.7%) 
> 2 8 (0.9%) 1 (2.4%) 0 (0%) 0 (0%) 
Not indicated 12 (1.3%) 1 (2.4%) 1 (2.1%) 1 (0.9%) 
In terms of transplant history, the patient sample comprised: 468 / 908 (51.5%) with 
successful transplants, 118 / 908 (13%) whose transplant had failed and 279 / 908 (30.7%) 
awaiting transplant (average wait 22.6 months). Some patients whose transplant had failed 
also reported they were „awaiting transplantation‟. Of the remainder, 237 / 908 (26.3%) were 
undergoing dialysis without transplantation and 57 / 908 (6.3%) had kidney disease not 
requiring dialysis. Renal Registry data [27] indicates 46.9% of patients have successful 
transplants (close to our figure). There are no data for the other patient characteristics. 
Amongst non-whites (including Asians) our sample included 18 / 69 patients (26%) with 
successful transplants and 10 / 69 (14.5%) whose transplant had failed; 35 / 69 patients 
(50.7%) were awaiting a transplant on dialysis (average wait: 21.45 months) and 3 / 69 
(4.3%) had kidney disease not requiring dialysis. These statistics cannot be compared with 
UK Renal Registry data since ethnicity is not recorded for such sub-groups [27]. However, a 
lower percentage figure for transplant success and a higher figure for patients awaiting 
transplants might be expected (ethnic minorities donate fewer organs and transplants are less 
likely to be closely matched). 
Of the 48 donor respondents, 21 were live donors and 27 relatives of deceased donors. 
Healthcare professionals comprised: 9 renal surgeons, 37 renal physicians, 17 transplant co-
ordinators, 31 nurses, 9 clinical scientists, 1 GP, 1 dietician, 1 network manager, 1 transplant 
scientist, 1 medical student, 1 transplant immunologist, 1 tissue typer, 1 clinical audit 
manager, 1 renal technologist and a pathologist. 
Data analysis 
Table 3 presents model 1 results including MRS 95% confidence intervals (CIs). Variables 
are as listed in Table 1. 
Table 3 Model 1: Results and MRS (i.e. utility value of other attributes expressed in terms of trade-off with 1 year waiting time) for 
patients, carers, donors, and healthcare workers 
Attribute Coefficient : 
Patients 
Implied MRS for 
patients 
 Coefficient : Dummies 
for the carer group 
Implied MRS for carers Wald test p-values: 
Carers vs. patients 
Wait .0443** 1  -.0156 1  
Tiss .0624** 1.41*  -.0407 0.76 p=0.0024 
(1.08 / 1.74)  (−1.42 / 2.93) 
Dep .0635** 1.43*  -.0585* 0.17 p<0.0001 
(1.17 / 1.69) (−1.54 / 1.89) 
Age .0069** 0.16*  .0006 0.26 p=0.0750 
(0.12 / 0.19) (−0.03 / 0.56 ) 
dis1 -.0004 −0.01  .1205 4.18 p=0.2965 
(−1.03 / 1.01) (−3.25 / 11.62) 
dis2 .6789** 15.32*  -.1971 16.79* p<0.0001 
(13.45 / 17.20) (2.69 / 30.89) 
ill1 -.1207** −2.73*  .1130 −0.27 p=0.1236 
(−1.45 / -4.00) (−9.55 / 9.01) 
ill2 .1850** 4.18*  -.0334 5.28 p=0.0910 
(3.12 / 5.23) (−2.27 / 12.83) 
Intercepts .1208**   -.0034   
Attribute Coefficient : 
Dummies for the 
donor group 
Implied MRS for 
donors 
Wald test p-values: 
Donors vs. patients 
Coefficient : Dummies 
for the healthcare 
worker group 
Implied MRS for 
healthcare workers 
Wald test p-values: 
Healthcare workers vs. 
patients 
Wait -.0086 1  -.0039 1  
Tiss -.0667* −0.12 p<0.0001 -.0110 1.27* p=0.0027 
(−1.62 / 1.38) (0.24 / 2.31) 
Dep -.0468* 0.47 p<0.0001 -.0003 1.56* p=0.0017 
(−0.79 / 1.73) (0.72 / 2.41) 
Age -.0023 0.13 p=0.0067 .0127** 0.48* p=0.0300 
(−0.05 / 0.31) (0.31 / 0.66) 
dis1 .1508 4.22 p=0.1669 .1823** 4.50* p=0.0265 
(−1.38 / 9.81) (1.09 / 7.91 ) 
dis2 -.2676* 11.54* p<0.0001 .1056 19.42* p<0.0001 
(2.90 / 20.17) (12.71 / 26.14) 
ill1 .0520 −1.93 p=0.2301 .0501 −1.75 p=0.1048 
(−8.66 / 4.80) (−5.74 / 2.24) 
ill2 .0245 5.87* p=0.1942 .1790* 9.01* p=0.9818 
(0.18 / 11.57) (5.44 / 12.59 ) 
Intercepts -.112   .0844   
*: Significant at 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates 
Coefficients are as indicated in Table 1. MRS in Table 3 indicates indirect utility values for 
changes in attributes (for direction of change see Table 1) relative to values for prioritizing a 
recipient waiting an extra year for transplantation (Additional file 4 Table 1 presents more 
detailed MRS formulae). In effect MRS indicates the rate at which the respondent group in 
question is willing to trade-off gains in relation to one criterion against losses in relation to 
another (in this case the amount of time waiting). MRS in Table 4 is expressed in terms of 1 
or 5 year waiting times. Measures of „goodness of fit‟ for model 1 (Random Effects probit) 
show that 63% of actual values are predicted by the model, and McFadden's R
2
 = 0.1088. A 
likelihood ratio test for the joint significance of the dummy variables has 27 degrees of 
freedom with a critical value of 40.11, compared with λ=71.90, so the dummy variables are 
jointly significant. The tissue match coefficient (tiss) in Table 4 indicates the impact of a 1% 
difference in 12 month kidney survival. Difference in survival rate between a perfect vs. 
favourable match is 1%, so the MRS figure of 1.41 (Table 3) also appears in Table 4 for 
„Prioritizing perfect not non-favourable tissue matches‟. Table 4 indicates MRS for the 
‟Prioritizing someone with a favourable not non-favourable match‟ (1.41 x 3 [a 3% difference 
in kidney survival rate] = 4.23). It also shows how much respondents value other changes in 
attributes compared to a 1 year wait (column 2). Moreover 5 year MRS figures are presented 
in Table 4 (column 3). If waiting time increases 5 fold, MRS for a 5 year wait is 1 / 5
th
 of 1 
year MRS. 95% CIs for 5 year MRS are 1 / 5
th
 of 1 year. The CIs define the range within 
which MRS figures must lie (to be 95% confident). 
Table 4 Model 1: MRS (i.e. utility value of other attributes expressed in terms of trade-off with 1 year or 5 year waiting time) for 
patients, carers, donors and healthcare workers 
Variable Patient trade-off between 
variable & 1 year wait 
Patient trade-off between 
variable & 5 years wait 
Carers trade-off between 
variable & 1 year wait 
Carers trade-off between 
variable & 5 years wait 
Prioritizing perfect not favourable tissue 
matches. 
1.41* 0.28* 0.76 0.15 
(1.08 / 1.74) (0.22 / 0.35) (−1.42 / 2.93) (−0.28 / 0.59) 
Prioritizing favourable not non- favourable 
tissue matches. 
4.23* 0.85* 2.27 0.45 
(3.23 / 5.22) (0.65 / 1.05) (−4.25 / 8.80) (−0.85 / 1.76) 
Prioritizing a recipient with dependents – 
per extra dependent 
1.43* 0.29* 0.17 0.03 
(1.17 / 1.69) (0.23 / 0.34) (−1.54 / 1.89) (−0.31 / 0.38) 
prioritizing a younger recipient – per year 
younger 
0.16* 0.03** 0.26 0.05 
(0.12 / 0.19) (0.02 / 0.04) (−0.03 / 0.56 ) (−.01 / 0.11) 
Prioritizing those with „no‟ not „moderate‟ 
diseases affecting life expectancy 
−0.01 0.00 4.18 0.84 
(−1.03 / 1.01) (−0.21 / 0.20) (−3.25 / 11.62) (−0.65 / 2.32) 
Prioritizing those with moderate not severe 
diseases affecting life expectancy 
15.32* 3.06* 16.79* 3.36* 
(13.45 / 17.20) (2.69 / 3.44) (2.69 / 30.89) 0.54 / 6.18) 
Prioritizing those with no not moderate 
diseases affecting QoL 
−2.73* −0.55* −0.27 −0.05 
(−1.45 / -4.00) (−0.29 / -0.80) (−9.55 / 9.01) (−1.91 / 1.80) 
Prioritizing those with moderate not severe 
diseases affecting QoL 
4.18* 0.84* 5.28 1.06 
(3.12 / 5.23) (0.62 / 1.05) (−2.27 / 12.83) (−0.45 / 2.57) 
Variable Donors trade-off between 
variable & 1 year wait 
Donors trade-off between 
variable & 5 year wait 
Healthcare workers trade-off 
between variable & 1 year wait 
Healthcare workers trade-off 
between variable & 5 year wait 
Prioritizing perfect not favourable tissue 
matches. 
−0.12 −0.02 1.27* 0.25 
(−1.62 / 1.38) (0.32 / 0.28) (0.24 / 2.31) (0.05 / 0.46) 
Prioritizing favourable not non- favourable 
tissue matches. 
−0.36 −0.07 3.82* 0.76* 
(−4.86 / 4.14) (−0.97/ 0.83) (0.72 / 6.93) (0.14 / 1.39) 
Prioritizing a recipient with dependents – 
per extra dependent 
0.47 0.09 1.56* 0.31* 
(−0.79 / 1.73) (−0.16 / 0.35) (0.72 / 2.41) (0.14 / 0.48) 
prioritizing a younger recipient – per year 
younger 
0.13 0.03 0.48* 0.10* 
(−0.05 / 0.31) (−0.01 / 0.06) (0.31 / 0.66) (0.06 / 0.13) 
Prioritizing those with no not moderate 
diseases affecting life expectancy 
4.22 0.84 4.50* 0.90* 
(−1.38 / 9.81) (−0.28 / 1.96) (1.09 / 7.91 ) (0.22 / 1.58) 
Prioritizing those with moderate not severe 
diseases affecting life expectancy 
11.54* 2.31* 19.42* 3.88* 
(2.90 / 20.17) (0.58 / 4.03) (12.71 / 26.14) (2.54 / 5.23) 
Prioritizing those with no not moderate 
diseases affecting QoL 
−1.93 −0.39 −1.75 −0.35 
(−8.66 / 4.80) (−1.73 / 0.96) (−5.74 / 2.24) (−1.15 / 0.45) 
Prioritizing those with moderate not severe 
diseases affecting QoL 
5.87* 1.17* 9.01* 1.80* 
(0.18 / 11.57) (0.04 / 2.31) (5.44 / 12.59 ) (1.09 / 2.52) 
*: Significant at 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates 
When interpreting results it might be expected that, in general, transplant preferences would 
lie in certain directions. On efficiency grounds improvements in kidney survival should be 
positively valued, and therefore respondents should generally prefer transplants with the 
highest chance of success. But, some stakeholder groups might not exhibit this preference if 
there is a lack of organs closely matching their own requirements. We might expect 
respondents to prioritize those waiting longer for a transplant on equity grounds, and 
therefore would anticipate a positive coefficient on a one year reduction in waiting time. It 
might also be considered that recipients with more dependents should be prioritized because 
more people would benefit from a recipient‟s improved health. In contrast, all other things 
being equal, one might expect older patients to benefit less because they have a lower life 
expectancy, so the coefficient on reductions in recipient age would be expected to be positive. 
Finally, for efficiency reasons respondents might prioritize more highly those with fewer or 
no disease(s) affecting life expectancy over those with moderate diseases. 
Patients‟ MRS figures (Table 4) suggest, all other things being equal (ceteris paribus), that 
patients would prioritize recipients with perfect over favourable tissue matches (tiss) more 
than those waiting an extra year (1 year MRS =1.41, exceeding indirect utility from avoiding 
a 1 year wait of 1.00). However, if a favourably matched patient were to wait 5 years longer, 
they would be a higher priority than the perfect match (MRS = 0.28) <1. Similarly, 
prioritizing someone with a favourable not non-favourable match (ceteris paribus) is valued 
more than prioritizing someone waiting for 1 year (MRS = 4.23) as it exceeds 1, the utility 
from a 1 year wait. But if a potential recipient waited 5 years longer, prioritizing the longest 
waiter is optimal (MRS = 0.85) < 1. 
Patients also prioritized someone with an extra dependent more than waiting a year longer 
(MRS for „dep‟=1.43). However, if a potential recipient waited 5 years longer MRS = 0.29, 
for an extra dependent, so prioritizing an extra dependent is a lower priority. Prioritizing a 
recipient who is 1 year younger is valued less than a 1 year or 5 year reduction in waiting 
time („age‟ 1 year MRS = 0.16, 5 year = 0.03). Patients would also not prioritize those with 
no vs. moderate diseases predominantly affecting life expectancy („dis 1‟ is insignificant), but 
would prioritize (dis2) those with moderate rather than severe diseases predominantly 
affecting life expectancy highly (1 year MRS = 15.32; 5 year MRS = 3.06). Thus, someone 
with a moderate, not severe, disease predominantly affecting life expectancy is prioritized 
(MRS >1). 
Paradoxically, for diseases predominantly affecting quality of life, rather than life 
expectancy, patients prioritized those with moderate not no disease („ill1‟ has a 1 year 
waiting time MRS of −2.73), perhaps because many patients have moderate co-morbid 
diseases. However, 5 year MRS equals −0.55, so long waiters are a higher priority than those 
with moderate rather than no disease affecting quality of life. Finally, patients prioritized 
those with moderate rather than severe diseases predominantly affecting quality of life („ill2‟ 
1 year MRS = 4.18; 5 year MRS = 0.84). So, ceteris paribus, someone with moderate not 
severe disease would be a higher priority than someone waiting 1 year longer (MRS>1), but a 
lower priority than someone waiting 5 years longer (MRS < 1). 
Carer results (Tables 3 and 4) were compromised to some extent by the smaller sample size 
(n=41), so MRS was only significant for 1 variable - prioritizing those with dependents (dep) 
(Table 3, column 5). The fact that other MRS figures are insignificant may partly be 
attributable to the size of sample. Wald test results (Table 3, column 7) indicate statistically 
significant differences in MRS between other stakeholder groups and patients (5% level). The 
results presented in Table 4 suggest MRS for prioritizing perfect over favourable tissue 
matches is lower amongst carers than patients (1 year MRS = insignificant vs. 1.41; 5 year 
MRS = insignificant vs. 0.28); and lower for prioritizing favourable over non-favourable 
matches (1 year MRS = insignificant vs 4.23; 5 year MRS = insignificant vs. 0.85). 
Moreover, Wald tests (Table 3, column 7) show carers‟ preference for prioritizing those with 
dependents is less than patients‟ (1 year MRS = insignificant vs. 1.43; 5 year MRS = 
insignificant vs. 0.29). Wald tests also show that carers prioritize those with moderate not 
severe diseases predominantly affecting life expectancy (dis2) more than do patients (1 year 
MRS = 16.79 vs. 15.32; 5 year MRS = 3.36 vs. 3.06). 
Donor response analysis was also compromised by a smaller sample size (n=48). This may 
explain why MRS (MRS for 1 and 5 years in Table 4) is only significant for 2 variables 
(„dis2‟ and „ill2‟). Once again, Wald tests (Table 3, column 4) suggest that donors value 
tissue match (tiss) less than patients (1 year MRS = insignificant vs. 1.41; 5 year MRS = 
insignificant vs. 0.28) for perfect not favourable matches, and also value favourable not non-
favourable matches less (1 year MRS = insignificant vs. 4.23; 5 year MRS = insignificant vs. 
0.85). Similar to carers, Wald tests (Table 3, column 4) indicate donors value prioritizing 
dependents (dep) less than patients do (1 year MRS = insignificant vs. 1.43; 5 year MRS = 
insignificant vs. 0.29). They also suggest that donors value prioritizing the young (age) less 
than patients (1 year MRS = insignificant vs. 0.16; 5 year MRS = insignificant vs. 0.03). 
Donors, in contrast to carers, prioritize those with moderate rather than severe co-morbidities 
predominantly affecting life expectancy less than do patients (1 year MRS = 11.54 vs. 15.32; 
5 years MRS = 2.31 vs. 3.06). Wald tests do not indicate other differences. 
Analysis of healthcare professionals‟ responses indicates MRS is significant for 6 / 7 
variables (Tables 3 and 4) and Wald tests (Table 3, column 7) suggest healthcare 
professionals‟ preferences differ from those of patients for 5 / 7 variables. Professionals value 
prioritizing those with better tissue matches „tiss‟ less than do patients (1 year MRS = 1.27 
vs. 1.41; 5 year MRS = 0.25 vs. 0.28) for perfect not favourable matches, and prioritize 
favourable vs. non-favourable matches less (1 year MRS = 3.82 vs. 4.23 ; 5 year MRS = 0.76 
vs. 0.85). Wald tests also indicate healthcare professionals prioritize those with dependents 
(dep) more (1 year MRS = 1.56 vs. 1.43; 5 year MRS = 0.31 vs. 0.29), and younger recipients 
(age) more (1 year MRS = 0.48 vs. 016; 5 year MRS = 0.10 vs. 0.03). They would also 
prioritize (dis1) those with no vs. moderate diseases affecting life expectancy whereas 
patients would not (1 year MRS = 4.50 vs insignificant; 5 year MRS = 0.90 vs. insignificant). 
Similarly, healthcare professionals also prioritized (dis2) those with moderate rather than 
severe diseases affecting life expectancy more than patients did (1 year MRS = 19.42 vs. 
15.32; 5 year MRS = 3.88 vs 3.06). However, there was no evidence that healthcare 
professionals would prioritize recipients with co-morbid diseases predominantly affecting 
quality of life differently from patients (Wald tests for ill1 and ill2 are insignificant). 
Importantly, the fact that healthcare professionals exhibit statistically significant differences 
to patients for 5 / 7 variables suggests that, if healthcare professionals‟ preferences were to 
prevail in transplant decision-making, this could result in transplant allocation decisions 
which inadequately reflect patient preferences. 
Measures of „goodness of fit‟ for model 2 indicate 62.09% actual values are predicted by the 
model, and McFadden's R
2
 = 0.133. A likelihood ratio test for the significance of the dummy 
variables has λ = 35.83, which compares with a critical value for 9 degrees of freedom of 
16.92, so the dummy variables are jointly significant. 
Table 5 compares ethnic minority and white majority patients (model 2). Coefficients are as 
defined in Table 1, and MRS specified in Additional file 4. Overall 3 dummy variables (tiss, 
dep and dis2) were significant, but Wald tests (Table 5, column 6) suggest more differences 
including the following. Ethnic minorities do not prioritize recipients with better tissue 
matches (tiss) but the majority population do (1 year MRS = insignificant vs. 1.54; 5 years 
MRS = insignificant vs. 0.31 for perfect rather than non-favourable matches). For favourable, 
rather than non-favourable, matches only white majority patients valued favourable matches 
significantly (1 year MRS = insignificant vs. 4.64; 5 years MRS = insignificant vs. 0.93). 
This is perhaps because ethnic minorities are disadvantaged if a close tissue match is 
required, due to a lack of ethnic minority donors. Wald test results indicate that MRS for 
prioritizing younger (age) rather than older recipients differs only marginally between ethnic 
minority and other patients (1 year MRS = 0.15 vs. 0.16; 5 year MRS = 0.03 vs. 0.03). 
Finally, Wald tests also suggest ethnic minority patients value prioritizing recipients with 
moderate vs. severe diseases (dis2) affecting life expectancy less than other patients (1 year 
MRS = 10.25 vs. 15.86; 5 year MRS = 2.05 vs 3.17). Once again, this is perhaps linked to the 
higher prevalence of severe diseases / co-morbidities predominantly affecting life expectancy 
amongst ethnic minorities. Wald tests did not indicate that valuation of other attributes varied 
by ethnicity. 
Table 5 Model 2: Patient values vs. those of ethnic minorities (96 out of 908 are ethnic minorities). Includes MRS expressed in terms of 
utility value of other attributes expressed in terms of trade-off with 1 year and 5 year waiting time 
Variable Coefficient for non-ethnic 
minorities 
MRS for non-ethnic minorities. Coefficient for dummy 
variables for ethnic 
minorities 
MRS for ethnic 
minority patients 
Wald test p-
values 
Wait .0451* 1 -.0061 1  
Tiss .0698* 1.54* -.0630** 0.17 p<0.0001 
(1.19 / 1.90) (−0.82 / 1.17) 
Dep .0595* 1.32* .0351* 2.42* p=0.2755 
(1.05 / 1.59) (1.40 / 3.44) 
Age .0071* 0.16* -.0011 0.15* p=0.0024 
(0.12 / 0.20) (0.03 / 0.27) 
dis1 .0039 0.09 -.0398 −0.92 p=0.6014 
(−0.98 / 1.15) (−4.41 / 2.57) 
dis2 .7158* 15.86* -.3153** 10.25* p<0.0001 
(13.87 / 17.85) (4.96 / 15.53) 
ill1 -.1085* −2.40* -.0903 −5.08* p=0.9050 
(−1.06 / -3.74) (−0.83 / -9.33) 
ill2 .1773* 3.93* .0647 6.19* p=0.2558 
(2.82 / 5.03) (2.51 / 9.88) 
Intercepts .1269*  -.0510   
Variable Non-ethnic minorities trade-
off between variable & 1 year 
wait 
Non-ethnic minorities trade-off 
between variable & 5 year wait 
Ethnic minority trade-
off between variable & 
1 year wait 
Ethnic minority 
trade-off between 
variable & 5 year wait 
 
Prioritizing perfect not favourable 
tissue matches. 
1.54* 0.31* 0.17 0.35  
(1.19 / 1.90) (0.24 / 0.38) (−0.82 / 1.17) (−0.16/ 0.23) 
Prioritizing favourable not non- 
favourable tissue matches. 
4.64* 0.93* 0.52 0.10  
(3.57 / 5.70) (0.71 / 1.14) (−2.46 / 3.50) (−0.49 / 0.70) 
Prioritizing a recipient with 
dependents – per extra dependent 
1.32* 0.26* 2.42** 0.48*  
(1.05 / 1.59) (0.21 / 0.32) (1.40 / 3.44) (0.28 / 0.69) 
prioritizing a younger recipient – 
per year younger 
0.16* 0.03* 0.15* 0.03*  
(0.12 / 0.20) (0.02 / 0.04) (0.03 / 0.27) (0.01 / 0.05) 
Prioritizing those with no not 
moderate diseases affecting life 
expectancy 
0.09 0.02 −0.92 −0.18  
(−0.98 / 1.15) (−0.20 / 0.23) (−4.41 / 2.57) (−0.88 / 0.51) 
Prioritizing those with moderate 
not severe diseases affecting life 
expectancy 
15.86* 3.17* 10.25* 2.05*  
(13.87 / 17.85) (2.77 / 3.57) (4.96 / 15.53) (0.99 / 3.11) 
Prioritizing those with no not 
moderate diseases affecting QoL 
−2.40* −0.48* −5.08* −1.02*  
(−1.06 / -3.74) (−0.21 / -0.75) (−0.83 / -9.33) (−0.17 / -1.87) 
Prioritizing those with moderate 
not severe diseases affecting QoL 
3.93* 0.79* 6.19* 1.24*  
(2.82 / 5.03) (0.56 / 1.01) (2.51 / 9.88) (0.50 / 1.98) 
*: Significant at the 5% level; Figures in parentheses indicate 95% confidence intervals for point estimates
Discussion 
This study is unique because, although DCEs have been used in relation to liver 
transplantation to identify public [17] and patient [16] preferences, this is the first application 
of DCEs exclusively relating to prioritizing renal transplants. Moreover, the detailed 
comparisons between stakeholder respondent groups are unprecedented. 
Usually when DCEs are used to address healthcare issues they look at patient preferences. In 
contrast our study compares preferences across a range of different stakeholder groups, 
deploying a new approach that had not been deployed in kidney transplant research before 
this project. The DCE approach allows for comparison of preferences between groups, and 
assessment of whether differences are statistically significant. Importantly, our findings 
indicate when stakeholder groups‟ preferences differ. This means that DCE studies that only 
elicit preferences for one group may fail to take into account preference heterogeneity. 
Establishing whether preferences vary between stakeholder groups (especially patients and 
healthcare professionals) is important for policy and practice. 
Although DCEs are increasingly used in health services research, one potential limitation can 
be the sensitivity of results to the choice of attributes presented, since it is only possible to 
indicate trade-offs in relation to the actual attributes selected. Therefore, it is essential to 
consult a wide range of opinion during the attribute selection process, including patients and 
professionals, before deciding upon which attributes to include. The present study included 
such a process. Constructing a robust DCE also requires that the choice of attributes has 
emerged from a thorough pilot exercise. In the present study, a great deal of time was 
invested in piloting the questionnaire to try to ensure that the range of attributes and levels 
identified for inclusion in our DCE questionnaires was appropriate. 
Our analysis of patient responses showed that respondents valued prioritizing patients with 
closer tissue matches, but also valued other factors significantly including prioritizing: long 
waiters; those with child or adult dependents; and younger recipients. Furthermore, in terms 
of co-morbidities affecting life expectancy, individuals with moderate diseases were 
prioritized over those with severe diseases, but those with moderate diseases were not 
prioritized over those with no such disease. In terms of diseases predominantly affecting 
quality of life (rather than life expectancy) patients prioritized recipients with moderate rather 
than no disease, and those with moderate rather than severe disease. However, for ethnic 
minority patients our findings demonstrate that, unlike other patients, this group did not value 
tissue match significantly. They also valued prioritizing those with severe rather than 
moderate disease affecting life expectancy less than other patients did. 
We are also able to report on the preferences of carers. Although the sample was small (n = 
41), it was sufficient to establish some statistically significant differences when compared 
with patients‟ responses, but probably insufficient for all differences in preferences between 
carers and patients to be demonstrated in a statistically significant manner. The number of 
carer responses obtained via our request in the publication „Kidney Life‟ was probably 
limited by the fact that this publication is read more by patients than those who care for renal 
patients. An alternative strategy would have been to ask patient respondents to supply the 
name and address of their carer (if applicable) to approach. However, despite the fact we only 
had 41 carer responses, this data was sufficient to establish that some carer preferences differ 
significantly from those of patients. In contrast to patients, carers did not value prioritizing 
those with better tissue matches or those with dependents. But, they did value prioritizing 
those with moderate not severe diseases affecting life expectancy more than patients. Whilst 
it is interesting that carer preferences differed from those of patients, patient preferences are 
clearly more important in terms of decisions on kidney transplant criteria. 
In terms of donor preferences, the sample size (n = 48 donor families / live donors) was 
sufficient to discern that some preferences differed in a statistically significant manner 
compared to those of patients. Our findings indicate that donors, like ethnic minority patients, 
did not value prioritizing better tissue matches significantly. They also valued transplants to 
those with dependents, younger recipients, and those with moderate rather than severe disease 
affecting life expectancy more than patients did. Donor preferences are important to establish 
because without donors transplantation programmes cannot continue. It might have been 
possible to obtain a larger sample of this stakeholder group if we had targeted people on the 
organ donor register as well as actual donor families and live donors, this would have 
increased statistical power thereby potentially allowing us to establish other statistically 
significant differences in preferences. 
The number of responses from healthcare professionals (n = 113) was more than adequate to 
discern preferences for the group as a whole. In terms of overall preferences, healthcare 
professionals‟ preferences differed from those of patients in that professionals valued 
prioritizing better tissue matches less than patients did, but valued prioritizing those with 
dependents more. They also prioritized those with no rather than moderate diseases 
predominantly affecting life expectancy whereas patients would not; and prioritised those 
with severe rather than moderate diseases affecting quality of life more than patients. 
Unfortunately, the sub-sample of renal physicians (as opposed to healthcare professionals 
more generally) was not large enough to establish how their preferences might differ from 
those of patients. Given that it is renal physicians who are involved in decisions about 
allocating kidneys, more detailed information on the preferences of this important group of 
healthcare professionals would have been useful. 
The difference between patients and healthcare professionals in prioritizing recipients with 
diseases affecting quality of life may be rationalized if patient preferences are biased due to 
many individuals in the patient group having moderate disease. However, it is less clear why 
healthcare professionals place less emphasis upon closeness of donor–recipient tissue match. 
In this respect, our findings indicate that if transplant allocation decisions and policies are 
based solely on healthcare professionals‟ own preferences this may conflict with patient 
wishes. 
In terms of relevance for transplant policy, our DCE study was not intended to identify 
specific individuals “who should be prioritized for renal transplantation”. Rather, it aimed to 
identify certain potential characteristics of kidney recipients characteristics which different 
stakeholder groups consider should be prioritized, and therefore suggest potential transplant 
recipient groups who ought to be made a higher or lower priority for transplantation. It is 
reassuring that our findings are broadly supportive of the 2006 revisions to UK kidney 
transplant policy in terms of prioritizing long waiters and young adults. However, although 
our analysis shows that this can be justified, it also suggests that other criteria (i.e. prioritizing 
those with dependents) ought to be considered. 
Our findings can be considered alongside a number of earlier non-DCE studies. An 
Australian-based renal study unlike ours adopted a general public perspective [10]. 
Respondents were found to prioritize long waiters and the young, but had a split verdict over 
whether to prioritize those with children. Similarly, renal research into African Americans‟ 
preferences [9] indicates that kidney allocation based upon HLA matching is considered 
unfair. However, at the same time, African Americans did not want to receive organs with 
lower survival rates; note since this paper was published (1997) graft survival for poorer 
matches has improved. More recently, a 2005 Glasgow renal study [11] has used a non-DCE 
scenario approach to consider allocation of deceased donor kidneys for transplantation. 
Interestingly, certain findings from this research conflict with our results (i.e. tissue matching 
was not a major allocation criterion) although, like our findings, the researchers reported that 
emphasis was placed on prioritizing long-waiters (albeit defined by time on dialysis, not on 
waiting lists). One DCE study, a 2010 Canadian article on patients with chronic kidney 
disease [19] has reported that respondents preferred to prioritize kidney transplants on the 
basis of a „best match‟ rather than „first come, first served.‟ However, in contrast to our study, 
this particular DCE considered a wide range of attributes relating to CKD in general 
(including organ procurement and the organization of care) and as such could provide only a 
very limited indication of preferences for kidney transplant allocation. The DCE included 
only one attribute relating to kidney transplants (“How should deceased donor kidneys for 
transplantation be allocated for transplantation”) with just two possible levels „best match‟, or 
„first come, first served.‟ Moreover, unlike our DCE study which furnished respondents with 
information on the likelihood of kidney transplants being successful for non-favourable 
matches, it is unclear whether similar information was provided in the Canadian study to 
ensure fully informed responses. 
Interestingly, a recent article which discusses new allocation concepts [28] emphasises 
efficiency criteria related to maximising health gains (i.e. getting the most life years from 
organs available for transplant). Whilst maximising life years or Quality Adjusted Life Years 
(QALYs) may be a legitimate transplant policy objective (and is supported by our findings in 
the sense that respondents value prioritizing younger patients in our DCE analysis), it is clear 
from our results that stakeholders also value equity considerations (i.e. avoiding patients 
having to face excessive waiting times). This is something which comes out strongly in our 
analysis of different stakeholders‟ priorities, but would be neglected in an approach which 
focuses upon maximising health gains. Furthermore, the findings reported here and in our 
earlier analysis [18] indicate that, although both time spent waiting and the quality of tissue 
match between donor and recipient are of importance to healthcare workers and patients, 
amongst ethnic minority patients closeness of tissue match is not a significant determinant of 
patient preferences. 
The findings reported in this paper, and those reported in our earlier analysis [18], suggest 
that both time spent waiting and the quality of tissue match between donor and recipient are 
of importance to healthcare workers and to non-ethnic minority patients, but that amongst 
ethnic minority patients closeness of tissue match is not a significant determinant of patient 
preferences. As DCEs can be used in order to quantify key stakeholders‟ willingness to 
„trade-off‟ between conflicting transplant allocation criteria, data from the present study 
could in principle be used to underpin kidney transplant allocation policy thereby increasing 
transparency [29]. For example, if the weightings obtained were to be used for informing 
organ allocation decisions then, rather like the MELD scores which underpin Liver transplant 
policy in the USA, this would increase transparency. However, such an approach would 
sideline other valid evidence [3,9-11,28,30] resulting in a more mechanistic process. In our 
view therefore such a mechanistic approach is inappropriate. 
The United Network for Organ Sharing (UNOS) policy takes into account the length of time 
spent on the waiting list; whether the potential organ candidate is a child; body size of both 
donor and candidate; tissue match between donor and candidate; blood type; and blood 
antibody levels. Although we wanted to avoid being too prescriptive about how either UK or 
USA transplant policy should be changed, in the light of our findings it is clear that changes 
to USA transplant policy in 2003, and UK transplant policy in 2006, have already led to a 
shift away from considerable reliance upon transplanting on the basis of a close HLA tissue 
match between donor and recipient. Changes to USA policy (7
th
 May 2003) involved an 
elimination of HLA-B similarity as a transplant allocation criterion [30]. This was because 
improvements to medications used to prevent transplant rejection reduced the benefit that 
previously had been associated with HLA-B matching (which had discriminated [perhaps 
unintentionally] against ethnic minorities). The current US policy has been suitably 
characterized as one of “Equal opportunity supplemented by fair innings” [31] and reported 
to have “improved access to transplantation for all minority groups” in the USA [28]. The 
first 6 year follow-up reported that the 2003 change in policy “has improved access to 
transplantation for all minority groups and has not been associated with a decrease in 2 year 
graft survival” [30]. Decreased emphasis on close tissue matching and more emphasis on 
prioritizing long waiters is similarly reported to have reduced the extent to which ethnic 
minority groups are disadvantaged in the UK [18]. 
However, our finding that UK ethnic minority patients do not value prioritizing recipients on 
the basis of closeness of tissue match indicates that there may be scope in the USA and the 
UK to consider further reducing the reliance upon donor-recipient HLA matching when 
allocating kidneys, without triggering a reduction in overall rates of graft survival if rates of 
graft survival continue to improve anyway. Such a policy shift would mean that the 
preferences of ethnic minority patients are better accommodated by transplant policy, 
alongside the preferences of other patients. More recently in 2011 [32] a USA concept 
document has been launched relating to kidney transplantation which advocates prioritizing 
the young because they have greater capacity to benefit. A problem with the approach is that 
whilst it might help maximize overall life expectancy from available transplants it 
discriminates against the old [32]. However, children are normally treated as an absolute 
priority, and our DCE analysis shows nothing to suggest otherwise. Indeed our findings 
indicate that this preference extends to young adults, which is not a completely new finding 
but important to make clear. 
A further step in extending the differentiation between patients on the transplant list would be 
to include social and medical factors as well as age. The issue of whether an allocation policy 
should treat people differently, either because they are felt to be more „deserving‟ or because 
allocating organs to some people and not others will give longer graft survival overall, is part 
of the equality/efficiency debate [3,18]. In this respect our study makes an important 
contribution. Our pilot study ruled out a preference for social factors such as prioritizing 
those in employment. Our main DCE findings did show a preference for allocation according 
to some co-morbidities affecting life expectancy or quality of life. Our research also indicates 
that a measure of „social value‟ (whether recipients have dependents) was valued by UK 
respondents. So, when transplant policy is re-appraised, consideration might be given to this 
additional criterion, though it is equally possible that the transplant policy group might not 
wish to include it for practical or ethical reasons. In either case, the use of DCEs to define and 
quantify stakeholders‟ preferences can provide a valid structure for the decision making 
process. 
Conclusions 
The findings of this study raise significant issues around transplant allocation to those from 
ethnic minority groups (who unlike other patients do not favour allocation on the basis of a 
close tissue match between donor and recipient; and also value prioritizing those with severe 
rather than moderate disease affecting life expectancy less than other patients do). Our 
findings also highlight important differences in preferences between healthcare professionals 
and patients (healthcare professionals prioritize better tissue matches less than patients do, 
but value prioritizing those with dependents more). Professionals would also prioritize those 
with no rather than moderate co-morbidities affecting life expectancy (more than patients), 
and would prioritize severe rather than moderate co-morbidities affecting quality of life more 
than patients would). Whilst respondents in our study did not think employment status should 
be a factor in kidney allocation, having dependents was valued. These findings ought to be 
considered when UK renal transplant policy is next re-appraised. This research also adds to 
the growing international literature relating to transplant allocation policy. 
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